NCT07220252View on ClinicalTrials.gov

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

January 1, 2030

Study Completion Date

June 30, 2033

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG

Ublituximab

Administered as an intravenous (IV) infusion.

DRUG

Placebo

Oral capsule.

DRUG

Placebo

IV infusion.

DRUG

Fingolimod

Oral capsule.

All Listed Sponsors

lead

TG Therapeutics, Inc.

INDUSTRY

NCT07220252 - Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis | Biotech Hunter | Biotech Hunter